This additional targeting is important for therapy, since the CAFs forming tumor stroma constitute about 25% of all live cells within the TME, and M2-type TAMs and mMDSCs representing activated myeloid cells within the TME of CT26 tumors collectively constitute about 40% of all immune (CD45+) cells and 15% of all live cells. Here, PTPRC is linked to neoplasm.